Antithrombotic Therapy After Acute Coronary Syndrome: Balancing Ischaemic Protection and Bleeding Risk
Antithrombotic therapy is central to preventing recurrent ischaemic events after acute coronary syndrome (ACS), yet it also increases bleeding, which is itself associated with adverse outcomes. This review summarises the mechanisms of coronary thrombosis, the pharmacology of antiplatelet and anticoagulant agents, and the evidence guiding the duration and intensity of dual antiplatelet therapy (DAPT). Twelve months of DAPT remains the default for most patients without high bleeding risk. In selected, clinically stable patients after percutaneous coronary intervention (PCI), shortened DAPT followed by P2Y12-inhibitor monotherapy reduced bleeding without an increase in ischaemic events in several randomised trials. However, immediate aspirin withdrawal after PCI did not show non-inferiority for ischaemic outcomes in NEO-MINDSET, with the excess events concentrated in the first month. Bleeding-risk tools, including the Academic Research Consortium high-bleeding-risk criteria and the PRECISE-DAPT score, together with patient characteristics, should inform treatment duration, particularly in older adults, patients with chronic kidney disease and those requiring oral anticoagulation. Evidence from Indian populations remains limited. Individualised treatment, reassessed as clinical circumstances change, offers the best balance between ischaemic protection and bleeding risk.
Authors
- Abinash. K.
- Monica. K.
- Manisha. M.
Institutions
- Tamil Nadu Dr. M.G.R. Medical University (IN)
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-20
- DOI
- https://doi.org/10.5281/zenodo.24394565
- Primary Topic
- Antiplatelet Therapy and Cardiovascular Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00